SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Samer Narouze, Honorio T. Benzon, David A. Provenzano, Asokumar Buvanendran, José De Andres, Timothy R. Deer, Richard Rauck, Marc A. Huntoon, Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications, Regional Anesthesia and Pain Medicine, 2015, 40, 3, 182

    CrossRef

  2. 2
    Eric M. Liotta, Kimberly E. Levasseur-Franklin, Andrew M. Naidech, Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban, Current Opinion in Critical Care, 2015, 21, 2, 127

    CrossRef

  3. 3
    Russell D. Hull, Meryl H. Gersh, The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants, Current Medical Research & Opinion, 2015, 31, 2, 197

    CrossRef

  4. 4
    John A. Cairns, Jeffrey I. Weitz, Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding, American Heart Journal, 2015, 169, 1, 1

    CrossRef

  5. 5
    Paul L. Hess, Michael J. Mirro, Hans-Christoph Diener, John W. Eikelboom, Sana M. Al-Khatib, Elaine M. Hylek, Hayden B. Bosworth, Bernard J. Gersh, Daniel E. Singer, Greg Flaker, Jessica L. Mega, Eric D. Peterson, John S. Rumsfeld, Benjamin A. Steinberg, Ajay K. Kakkar, Robert M. Califf, Christopher B. Granger, Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012, American Heart Journal, 2014, 168, 3, 239

    CrossRef

  6. 6
    Timothy Vo, Sara Vazquez, Matthew T. Rondina, Current State of Anticoagulants to Treat Deep Venous Thrombosis, Current Cardiology Reports, 2014, 16, 3

    CrossRef

  7. 7
    Linda Stang, Susan Nahirniak, Ken Butcher, Artur J. Szkotak, Dabigatran assessment in patients with acute complications using routine coagulation assays, Blood Coagulation & Fibrinolysis, 2014, 25, 5, 426

    CrossRef

  8. 8
    P. Fontana, S. Z. Goldhaber, H. Bounameaux, Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism, European Heart Journal, 2014, 35, 28, 1836

    CrossRef

  9. 9
    Sebastian Ewen, Volker Rettig-Ewen, Felix Mahfoud, Michael Böhm, Ulrich Laufs, Drug adherence in patients taking oral anticoagulation therapy, Clinical Research in Cardiology, 2014, 103, 3, 173

    CrossRef

  10. 10
    Michael Levine, Joshua N. Goldstein, Emergency Reversal of Anticoagulation: Novel Agents, Current Neurology and Neuroscience Reports, 2014, 14, 8

    CrossRef

  11. 11
    D. M. Siegal, D. A. Garcia, M. A. Crowther, How I treat target-specific oral anticoagulant-associated bleeding, Blood, 2014, 123, 8, 1152

    CrossRef

  12. 12
    Ingrid Pabinger, Wilfried Lang, Franz Xaver Roithinger, Franz Weidinger, Sabine Eichinger-Hasenauer, Reinhold Glehr, Walter-Michael Halbmayer, Hans-Peter Haring, Bernd Jilma, Hans Christian Korninger, Sibylle Kozek-Langenecker, Paul Kyrle, Herbert Watzke, Ansgar Weltermann, Johann Willeit, Kurt Huber, Konsensus-Statement – Schlaganfallprophylaxe bei nicht-valvulärem Vorhofflimmern unter besonderer Berücksichtigung der direkten oralen Antikoagulanzien, Wiener klinische Wochenschrift, 2014, 126, 23-24, 792

    CrossRef

  13. 13
    W. Frank Peacock, Managing Bleeding and Emergency Reversal of Newer Oral Anticoagulants: A Review for Primary Care Providers, Hospital Practice, 2014, 42, 4, 75

    CrossRef

  14. 14
    Dieter Adelmann, Marion Wiegele, Rudolf Karl Wohlgemuth, Stefan Koch, Sophie Frantal, Peter Quehenberger, Gisela Scharbert, Sibylle Kozek–Langenecker, Eva Schaden, Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry, Thrombosis Research, 2014, 134, 4, 918

    CrossRef

  15. 15
    B. A. Konkle, Monitoring target-specific oral anticoagulants, Hematology, 2014, 2014, 1, 329

    CrossRef

  16. 16
    Neville M. Gibbs, William M. Weightman, Stephen A. Watts, New antithrombotic agents in the ambulatory setting, Current Opinion in Anaesthesiology, 2014, 27, 6, 589

    CrossRef

  17. 17
    Mika Skeppholm, Paul Hjemdahl, Jovan P. Antovic, Josephine Muhrbeck, Jaak Eintrei, Yuko Rönquist-Nii, Anton Pohanka, Olof Beck, Rickard E. Malmström, On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation, Thrombosis Research, 2014, 134, 4, 783

    CrossRef

  18. 18
    David Feinbloom, Periprocedural management of antithrombotic therapy in hospitalized patients, Journal of Hospital Medicine, 2014, 9, 5
  19. 19
    Steven Deitelzweig, Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation, Cardiovascular Therapeutics, 2014, 32, 2
  20. 20
    Deborah M. Siegal, Adam Cuker, Reversal of target-specific oral anticoagulants, Drug Discovery Today, 2014, 19, 9, 1465

    CrossRef

  21. 21
    I. Gouin-Thibault, C. Flaujac, X. Delavenne, S. Quenet, M.-H. Horellou, S. Laporte, V. Siguret, T. Lecompte, Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays, Thrombosis and Haemostasis, 2013, 111, 2, 240

    CrossRef

  22. 22
    J. Douxfils, J.-M. Dogné, F. Mullier, B. Chatelain, Y. Rönquist-Nii, R. E. Malmström, P. Hjemdahl, Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate, Thrombosis and Haemostasis, 2013, 110, 3, 543

    CrossRef

  23. 23
    Jovan P. Antovic, Mika Skeppholm, Jaak Eintrei, Elisabet Eriksson Boija, Lisbeth Söderblom, Eva-Marie Norberg, Liselotte Onelöv, Yuko Rönquist-Nii, Anton Pohanka, Olof Beck, Paul Hjemdahl, Rickard E. Malmström, Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma, European Journal of Clinical Pharmacology, 2013, 69, 11, 1875

    CrossRef

  24. 24
    J. Desai, J. M. Kolb, J. I. Weitz, J. Aisenberg, Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies, Thrombosis and Haemostasis, 2013, 110, 2, 205

    CrossRef

  25. 25
    Giovanni Di Minno, Elena Ricciardi, Antonella Scalera, Laboratory tests during direct oral anticoagulant treatment? No, Internal and Emergency Medicine, 2013, 8, 5, 367

    CrossRef

  26. 26
    David Keeling, Raza Alikhan, Management of venous thromboembolism – controversies and the future, British Journal of Haematology, 2013, 161, 6
  27. 27
    H. T. Benzon, M. J. Avram, D. Green, R. O. Bonow, New oral anticoagulants and regional anaesthesia, British Journal of Anaesthesia, 2013, 111, suppl 1, i96

    CrossRef

  28. 28
    Jay Desai, Christopher B. Granger, Jeffrey I. Weitz, James Aisenberg, Novel oral anticoagulants in gastroenterology practice, Gastrointestinal Endoscopy, 2013, 78, 2, 227

    CrossRef

  29. 29
    Sean Yates, Ravi Sarode, Novel thrombin and factor Xa inhibitors, Current Opinion in Hematology, 2013, 20, 6, 552

    CrossRef

  30. 30
    Waleed Ghanima, Dan Atar, Per Morten Sandset, Nye perorale antikoagulasjonsmidler – en oversikt, Tidsskrift for Den norske legeforening, 2013, 133, 18, 1940

    CrossRef

  31. 31
    Aaron Liew, James Douketis, Perioperative management of patients who are receiving a novel oral anticoagulant, Internal and Emergency Medicine, 2013, 8, 6, 477

    CrossRef

  32. 32
    M. M. Kawiorski, A. Alonso-Canovas, A. de Felipe Mimbrera, S. Sainz de la Maza, R. Alvarez-Velasco, B. Zarza, J. Masjuan, Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment, Thrombosis and Haemostasis, 2013, 111, 3, 557

    CrossRef